QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

ABSTRACT: This is an open-label, muticenter phase II study to evaluate the efficacy and safety of QL1706 monotherapy or in combination with bevacizumab and XELOX as first-line treatment of unresectable advanced or metastatic CRC.

DISEASE(S): Colorectal Carcinoma,Colorectal Neoplasms

PROVIDER: 13857 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR